1.	Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14387, 2009-012787-14, NCT01103323
2.	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14874, 2009-017957-37, NCT01271712
3.	A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11726, 2008-000107-28, NCT00664326
4.	Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14596, 2009-012570-13, NCT01003015
5.	Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 09-400, NCT01068769
6.	First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11728, 2010-020121-41, NCT01289821
7.	Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11656, 2008-007151-27, NCT00934882
8.	Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors. Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13172, NCT00960258
9.	Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14996, NCT01096030
10.	Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: 11651, NCT01117623
11.	Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14458, NCT01187615
12.	BAY73-4506 Probe Substrate Study Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12434, NCT01287598
13.	Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity Phase: Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14814, NCT01339104
14.	WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib Phase: No phase specified Type: Diagnostic Status: Completed Age: Not specified Sponsor: Other Protocol IDs: S52989, NCT01265979